CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new preclinical data on ponatinib, the company’s investigational multi-targeted tyrosine kinase inhibitor, will be presented at the American Association for Cancer Research (AACR) Annual Meeting to be held April 2-6, 2011 in Orlando, FL.
